EP2213661A1 — c-Met Modulators and Methods of Use
Assigned to Exelixis Inc · Expires 2010-08-04 · 16y expired
What this patent protects
The present invention provides a compound for modulating protein kinase enzymatic activity for modulating cellular activities such as proliferation, differentiation, programmed cell death, migration and chemoinvasion. More specifically, the invention provides a quinazoline deriva…
USPTO Abstract
The present invention provides a compound for modulating protein kinase enzymatic activity for modulating cellular activities such as proliferation, differentiation, programmed cell death, migration and chemoinvasion. More specifically, the invention provides a quinazoline derivative which inhibits, regulates and/or modulates kinase receptor, particularly c-Met, KDR, c-Kit, fit-3 and fit-4, signal transduction pathways related to the changes in cellular activities as mentioned above. The compound of the present invention is represented by the following structure:
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.